Cyclacel Pharmaceuticals Inc (CYCC) — Tangible Net Worth Ratio
Cyclacel Pharmaceuticals Inc (CYCC) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($3.63K) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore CYCC year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Cyclacel Pharmaceuticals Inc Tangible Net Worth Ratio (2004–2023)
This chart shows how Cyclacel Pharmaceuticals Inc's Tangible Net Worth Ratio has changed across 20 annual periods from 2004 to 2023. As of June 2025, the ratio stands at 100.0%, reflecting net assets of $3.63K with intangible assets of $0.00 USD. For live market cap and overall valuation, see Cyclacel Pharmaceuticals Inc market capitalisation.
Annual Tangible Net Worth Ratio for Cyclacel Pharmaceuticals Inc (2004–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for Cyclacel Pharmaceuticals Inc from 2004 to 2023, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore Cyclacel Pharmaceuticals Inc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 100.0% | $607.00K | $0.00 | $8.80 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $20.43 Million | $0.00 | $28.05 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $37.69 Million | $0.00 | $43.14 Million | ▲ +0.0 pp |
| 2020 | 100.0% | $33.26 Million | $0.00 | $36.80 Million | ▲ +0.0 pp |
| 2019 | 100.0% | $11.70 Million | $0.00 | $15.31 Million | ▲ +0.0 pp |
| 2018 | 100.0% | $15.27 Million | $0.00 | $19.82 Million | ▲ +0.0 pp |
| 2017 | 100.0% | $21.77 Million | $0.00 | $26.00 Million | ▲ +0.0 pp |
| 2016 | 100.0% | $14.27 Million | $0.00 | $19.66 Million | ▲ +0.0 pp |
| 2015 | 100.0% | $18.84 Million | $0.00 | $24.76 Million | ▲ +0.0 pp |
| 2014 | 100.0% | $21.69 Million | $0.00 | $29.39 Million | ▲ +0.0 pp |
| 2013 | 100.0% | $28.02 Million | $0.00 | $35.52 Million | ▲ +0.0 pp |
| 2012 | 100.0% | $10.02 Million | $0.00 | $19.35 Million | ▲ +0.0 pp |
| 2011 | 100.0% | $19.50 Million | $0.00 | $26.00 Million | ▲ +0.0 pp |
| 2010 | 100.0% | $24.92 Million | $0.00 | $31.46 Million | ▲ +0.0 pp |
| 2009 | 100.0% | $4.64 Million | $0.00 | $14.47 Million | ▲ +0.0 pp |
| 2008 | 100.0% | $20.64 Million | $0.00 | $30.96 Million | ▲ +7.4 pp |
| 2007 | 92.6% | $57.97 Million | $4.30 Million | $75.91 Million | ▼ -2.3 pp |
| 2006 | 94.9% | $53.92 Million | $2.75 Million | $63.28 Million | ▼ -5.1 pp |
| 2005 | 100.0% | $14.60 Million | $0.00 | $21.45 Million | ▲ +0.0 pp |
| 2004 | 100.0% | $44.12 Million | $0.00 | $55.60 Million | — |